Matinas BioPharma Holdings Inc (MTNB)
Matinas Biopharma Holdings is a biopharmaceutical company focused on development of its product candidate: MAT9001, a purified, prescription-only omega-3 free fatty acid formulation designed for the treatment of cardiovascular and metabolic conditions; and the application of its lipid nano-crystal (LNC) platform delivery technology to solve challenges relating to the delivery of small molecules, vaccines, proteins and peptides. Co.'s lead drug candidate based on the LNC platform delivery technology is MAT2203, which is an antifungal drug. Co.'s second clinical stage LNC-based product candidate is MAT2501, an orally administered formulation of aminoglycoside antibiotic amikacin.
|
Free MTNB Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (4.00 out of 4) 86th percentile
(ranked higher than approx. 86% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|